Abstract:
A method of making an aliphatic polyester prepolymer, comprising: reacting, alone or in combination with other reactants, a diol with at least a first diacid (or a diester of said first diacid) to produce an aliphatic polyester prepolymer. The first diacid is preferably a trans-beta-hydromuconic acid (HMA). In some embodiments, the diol contains at least one ether linkage. In some embodiments the diol is further reacted with at a second diacid, or a diester of said second diacid, wherein said second diacid is different from said first diacid. Prepolymers produced from such processes and articles formed therefrom are also described.
Abstract:
A method of making an aliphatic polyester prepolymer, comprising: reacting, alone or in combination with other reactants, a diol with at least a first diacid (or a diester of the first diacid) to produce an aliphatic polyester prepolymer. The first diacid is preferably a trans-beta-hydromuconic acid (HMA). In some embodiments, the diol contains at least one ether linkage. In some embodiments the diol is further reacted with at a second diacid, or a diester of the second diacid, wherein the second diacid is different from the first diacid. Prepolymers produced from such processes and articles formed therefrom are also described.
Abstract:
The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
Abstract:
A MEMS fuze having a moveable slider with a microdetonator at an end for positioning adjacent an initiator. A setback activated lock and a spin activated lock prevent movement of the slider until respective axial and centrifugal acceleration levels have been achieved. Once these acceleration levels are achieved, the slider is moved by a V-beam shaped actuator arrangement to position the microdetonator relative to a secondary lead to start an explosive train in a munitions round.
Abstract:
The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
Abstract:
The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
Abstract:
Presently described are microstructured articles such as a brightness enhancing film or optical turning film. The microstructured articles comprise a brightness enhancing polymerized structure comprising the reaction product of a composition comprising an organic component having at least one oligomeric urethane (meth)acrylate and surface modified silica nanoparticles.
Abstract:
In general, the invention is directed to a patient programmer for an implantable medical device. The patient programmer may include one or more of a variety of features that may enhance performance, support mobility and compactness, or promote patient convenience.
Abstract:
A catheter body includes an exit port over which a pressure responsive sleeve is formed that allows material to exit a lumen of the catheter body at a given pressure. In one embodiment, a surface of the sleeve is approximately flush with a surface of the catheter body.
Abstract:
The present invention provides pressure-sensitive adhesives having a refractive index of at least 1.48. The pressure-sensitive adhesives comprise at least one monomer containing a substituted or an unsubstituted aromatic moiety.